help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moghetti, P.
Right arrow Articles by Muggeo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moghetti, P.
Right arrow Articles by Muggeo, M.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 1 139-146
Copyright © 2000 by The Endocrine Society


Original Studies

Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles, and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled 6-Month Trial, followed by Open, Long-Term Clinical Evaluation1

Paolo Moghetti, Roberto Castello, Carlo Negri, Flavia Tosi, Fabrizia Perrone, Marco Caputo, Elisabetta Zanolin and Michele Muggeo

Division of Endocrinology and Metabolic Diseases (P.M., R.C., C.N., F.T., F.P., M.M.), and Division of Medical Statistics (E.Z.), University of Verona, Verona; Laboratory of Clinical Chemistry (M.C.), Ospedale Maggiore, Verona, Italy

Address correspondence and requests for reprints to: Dr. Paolo Moghetti, Divisione di Endocrinologia e Malattie del Metabolismo, Ospedale Maggiore, P.le Stefani, 1 I-37126 Verona, Italy. E-mail: moghetti{at}iol.it

In the last few years some studies assessed the effects of attenuation of hyperinsulinemia and insulin resistance, obtained by insulin sensitizing agents, in women with polycystic ovary syndrome (PCOS), suggesting potential scope for these drugs in treating the whole spectrum of reproductive, endocrine, and metabolic abnormalities found in such subjects. However, the results of these studies, mostly uncontrolled and short-term, are still inconclusive, and there is no long-term follow-up. In the present study, 23 PCOS subjects [mean (± SE) body mass index 30.0 ± 1.1 kg/m2] were randomly assigned to double-blind treatment with metformin (500 mg tid) or placebo for 6 months, while maintaining their usual eating habits. Before and after treatment, menstrual history, endocrine and metabolic profiles, serum 17-hydroxyprogesterone response to GnRH-agonist testing, and insulin sensitivity measured by the glucose clamp technique were assessed. Eighteen of these women, as well as 14 additional PCOS patients, were subsequently given metformin in an open trial for 11.0 ± 1.3 months (range 4–26), to assess long-term effects of treatment and baseline predictors of metformin efficacy on reproductive abnormalities. After metformin treatment, mean frequency of menstruation improved (P = 0.002), due to striking amelioration of menstrual abnormalities in about 50% of subjects. Women given metformin showed reduced plasma insulin (at fasting: P = 0.057; during the clamp studies: P < 0.01) and increased insulin sensitivity (P < 0.05). Concurrently, ovarian hyperandrogenism was attenuated, as indicated by significant reductions in serum free testosterone (P < 0.05) and in the 17-hydroxyprogesterone response to GnRH-agonist testing (P < 0.05). No changes were found in the placebo group. Only comparable minor changes in body mass index were found both in the metformin group and in the placebo group. In the open, long-term trial 17 women (54.8%) showed striking improvements of their menstrual abnormalities and were considered as responders. Logistic regression analysis of baseline characteristics in responders and nonresponders showed that plasma insulin, serum androstenedione, and menstrual history were independent predictors of the treatment’s clinical efficacy. In 10 subjects whose menses proved regular after treatment, the great majority of cycles became ovulatory (32 out of 39 assessed, 79%). In conclusion, in women with PCOS metformin treatment reduced hyperinsulinemia and hyperandrogenemia, independently of changes in body weight. In a large number of subjects these changes were associated with striking, sustained improvements in menstrual abnormalities and resumption of ovulation. Higher plasma insulin, lower serum androstenedione, and less severe menstrual abnormalities are baseline predictors of clinical response to metformin.




This article has been cited by other articles:


Home page
Reproductive SciencesHome page
M. Aubuchon, H. Lieman, D. Stein, H. W. Cohen, B. Isaac, G. Adel, V. Weitzman, M. Tetrokalashvili, A. J. Polotsky, and N. Santoro
Metformin Does Not Improve the Reproductive or Metabolic Profile in Women With Polycystic Ovary Syndrome (PCOS)
Reproductive Sciences, October 1, 2009; 16(10): 938 - 946.
[Abstract] [PDF]


Home page
EndocrinologyHome page
S. Rice, L. Pellatt, K. Ramanathan, S. A. Whitehead, and H. D. Mason
Metformin Inhibits Aromatase via an Extracellular Signal-Regulated Kinase-Mediated Pathway
Endocrinology, October 1, 2009; 150(10): 4794 - 4801.
[Abstract] [Full Text] [PDF]


Home page
Diabetes and Vascular Disease ResearchHome page
K. I. Cheang, J. M. Huszar, A. M. Best, S. Sharma, P. A. Essah, and J. E. Nestler
Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome
Diabetes and Vascular Disease Research, April 1, 2009; 6(2): 110 - 119.
[Abstract] [PDF]


Home page
Endocr. Rev.Home page
S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr.
Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review
Endocr. Rev., February 1, 2009; 30(1): 1 - 50.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. Moll, J.C. Korevaar, P.M.M. Bossuyt, and F. van der Veen
Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?
Hum. Reprod., August 1, 2008; 23(8): 1830 - 1834.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Cosma, B. A. Swiglo, D. N. Flynn, D. M. Kurtz, M. L. LaBella, R. J. Mullan, M. B. Elamin, P. J. Erwin, and V. M. Montori
Insulin Sensitizers for the Treatment of Hirsutism: A Systematic Review and Metaanalyses of Randomized Controlled Trials
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1135 - 1142.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. S. Legro, H. X. Barnhart, W. D. Schlaff, B. R. Carr, M. P. Diamond, S. A. Carson, M. P. Steinkampf, C. Coutifaris, P. G. McGovern, N. A. Cataldo, et al.
Ovulatory Response to Treatment of Polycystic Ovary Syndrome Is Associated with a Polymorphism in the STK11 Gene
J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 792 - 800.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. E. S. Salley, E. P. Wickham, K. I. Cheang, P. A. Essah, N. W. Karjane, and J. E. Nestler
POSITION STATEMENT: Glucose Intolerance in Polycystic Ovary Syndrome A Position Statement of the Androgen Excess Society
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4546 - 4556.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
E. Moll, F. van der Veen, and M. van Wely
The role of metformin in polycystic ovary syndrome: a systematic review
Hum. Reprod. Update, November 1, 2007; 13(6): 527 - 537.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
B. Trolle, A. Flyvbjerg, U. Kesmodel, and F.F. Lauszus
Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial
Hum. Reprod., November 1, 2007; 22(11): 2967 - 2973.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Palomba, A. Falbo, T. Russo, F. Manguso, A. Tolino, F. Zullo, P. De Feo, and F. Orio Jr.
Insulin Sensitivity after Metformin Suspension in Normal-Weight Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3128 - 3135.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
F. Orio, F. Manguso, S. Di Biase, A. Falbo, F. Giallauria, D. Labella, A. Tolino, G. Lombardi, A. Colao, and S. Palomba
Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study
Eur. J. Endocrinol., July 1, 2007; 157(1): 69 - 73.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Codner and H. F. Escobar-Morreale
Hyperandrogenism and Polycystic Ovary Syndrome in Women with Type 1 Diabetes Mellitus
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1209 - 1216.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
C. Meyer, B. P. McGrath, and H. J. Teede
Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome
Diabetes Care, March 1, 2007; 30(3): 471 - 478.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Gambineri, L. Patton, A. Vaccina, M. Cacciari, A. M. Morselli-Labate, C. Cavazza, U. Pagotto, and R. Pasquali
Treatment with Flutamide, Metformin, and Their Combination Added to a Hypocaloric Diet in Overweight-Obese Women with Polycystic Ovary Syndrome: A Randomized, 12-Month, Placebo-Controlled Study
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3970 - 3980.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
S.K. Blank, C.R. McCartney, and J.C. Marshall
The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome
Hum. Reprod. Update, July 1, 2006; 12(4): 351 - 361.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
K. Rautio, J.S. Tapanainen, A. Ruokonen, and L.C. Morin-Papunen
Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study
Hum. Reprod., June 1, 2006; 21(6): 1400 - 1407.
[Abstract] [Full Text] [PDF]


Home page
ReproductionHome page
V. Sander, C. G. Luchetti, M. E. Solano, E. Elia, G. Di Girolamo, C. Gonzalez, and A. B. Motta
Role of the N, N'-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone.
Reproduction, March 1, 2006; 131(3): 591 - 602.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Eisenhardt, N. Schwarzmann, V. Henschel, A. Germeyer, M. von Wolff, A. Hamann, and T. Strowitzki
Early Effects of Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomized, Double-Blind, Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 946 - 952.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
T. Tang, J. Glanville, C. J. Hayden, D. White, J. H. Barth, and A. H. Balen
Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study
Hum. Reprod., January 1, 2006; 21(1): 80 - 89.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
N. A. Cataldo, F. Abbasi, T. L. McLaughlin, M. Basina, P. Y. Fechner, L. C. Giudice, and G. M. Reaven
Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome
Hum. Reprod., January 1, 2006; 21(1): 109 - 120.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Yilmaz, N. Bukan, G. Ayvaz, A. Karakoc, F. Toruner, N. Cakir, and M. Arslan
The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome
Hum. Reprod., December 1, 2005; 20(12): 3333 - 3340.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Orio Jr., S. Palomba, T. Cascella, B. De Simone, F. Manguso, S. Savastano, T. Russo, A. Tolino, F. Zullo, G. Lombardi, et al.
Improvement in Endothelial Structure and Function after Metformin Treatment in Young Normal-Weight Women with Polycystic Ovary Syndrome: Results of a 6-Month Study
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6072 - 6076.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
L. Ibanez, A. M. Jaramillo, A. Ferrer, and F. de Zegher
High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception
Hum. Reprod., September 1, 2005; 20(9): 2457 - 2462.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
R. Homburg
Clomiphene citrate--end of an era? a mini-review
Hum. Reprod., August 1, 2005; 20(8): 2043 - 2051.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
D. Ertunc, E.C. Tok, A. Aktas, E.M. Erdal, and S. Dilek
The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome
Hum. Reprod., May 1, 2005; 20(5): 1207 - 1212.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. V. Mehta, K. S. Patel, M. S. Coffler, M. H. Dahan, R. Y. Yoo, J. S. Archer, P. J. Malcom, and R. J. Chang
Luteinizing Hormone Secretion Is Not Influenced by Insulin Infusion in Women with Polycystic Ovary Syndrome Despite Improved Insulin Sensitivity during Pioglitazone Treatment
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2136 - 2141.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. B. Kilicdag, T. Bagis, H. B. Zeyneloglu, E. Tarim, E. Aslan, B. Haydardedeoglu, and S. Erkanli
Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study
Hum. Reprod., April 1, 2005; 20(4): 894 - 899.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
K Rautio, J S Tapanainen, A Ruokonen, and L C Morin-Papunen
Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome
Eur. J. Endocrinol., February 1, 2005; 152(2): 269 - 275.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
V. Jayagopal, E. S. Kilpatrick, S. Holding, P. E. Jennings, and S. L. Atkin
Orlistat Is as Beneficial as Metformin in the Treatment of Polycystic Ovarian Syndrome
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 729 - 733.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
V. Sepilian and M. Nagamani
Effects of Rosiglitazone in Obese Women with Polycystic Ovary Syndrome and Severe Insulin Resistance
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 60 - 65.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A.S. Sonmez, L. Yasar, K. Savan, S. Koc, J. Ozcan, A. Toklar, F. Yazicioglu, A. Akgun, and N. Sut
Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome
Hum. Reprod., January 1, 2005; 20(1): 175 - 179.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
S. Kashyap, G. A. Wells, and Z. Rosenwaks
Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome
Hum. Reprod., November 1, 2004; 19(11): 2474 - 2483.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Palomba, F. Orio Jr., L. G. Nardo, A. Falbo, T. Russo, D. Corea, P. Doldo, G. Lombardi, A. Tolino, A. Colao, et al.
Metformin Administration Versus Laparoscopic Ovarian Diathermy in Clomiphene Citrate-Resistant Women with Polycystic Ovary Syndrome: A Prospective Parallel Randomized Double-Blind Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4801 - 4809.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Brettenthaler, C. De Geyter, P. R. Huber, and U. Keller
Effect of the Insulin Sensitizer Pioglitazone on Insulin Resistance, Hyperandrogenism, and Ovulatory Dysfunction in Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3835 - 3840.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. Vanky, K.A. Salvesen, R. Heimstad, K.J. Fougner, P. Romundstad, and S.M. Carlsen
Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study
Hum. Reprod., August 1, 2004; 19(8): 1734 - 1740.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. A. Ganie, M. L. Khurana, M. Eunice, M. Gulati, S. N. Dwivedi, and A. C. Ammini
Comparison of Efficacy of Spironolactone with Metformin in the Management of Polycystic Ovary Syndrome: An Open-Labeled Study
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2756 - 2762.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
C.J. Glueck, N. Goldenberg, J. Pranikoff, M. Loftspring, L. Sieve, and P. Wang
Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy
Hum. Reprod., June 1, 2004; 19(6): 1323 - 1330.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
S.B. Kjotrod, V. von During, and S.M. Carlsen
Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study
Hum. Reprod., June 1, 2004; 19(6): 1315 - 1322.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
I. Leclerc, W. W. Woltersdorf, G. da Silva Xavier, R. L. Rowe, S. E. Cross, G. S. Korbutt, R. V. Rajotte, R. Smith, and G. A. Rutter
Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E1023 - E1031.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
D. J. Salmi, H. C. Zisser, and L. Jovanovic
Screening for and Treatment of Polycystic Ovary Syndrome in Teenagers
Experimental Biology and Medicine, May 1, 2004; 229(5): 369 - 377.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
R. Homburg and C. B. Lambalk
Polycystic ovary syndrome in adolescence--a therapeutic conundrum
Hum. Reprod., May 1, 2004; 19(5): 1039 - 1042.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Ibanez and F. de Zegher
Ethinylestradiol-Drospirenone, Flutamide-Metformin, or Both for Adolescents and Women with Hyperinsulinemic Hyperandrogenism: Opposite Effects on Adipocytokines and Body Adiposity
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1592 - 1597.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. Vanky, K.A. Salvesen, and S.M. Carlsen
Six-month treatment with low-dose dexamethasone further reduces androgen levels in PCOS women treated with diet and lifestyle advice, and metformin
Hum. Reprod., March 1, 2004; 19(3): 529 - 533.
[Abstract] [Full Text] [PDF]


Home page
Clin Med ResHome page
M. T. Sheehan
Polycystic Ovarian Syndrome: Diagnosis and Management
Clin. Med. Res., February 1, 2004; 2(1): 13 - 27.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)
Hum. Reprod., January 1, 2004; 19(1): 41 - 47.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. S. Coffler, K. Patel, M. H. Dahan, R. Y. Yoo, P. J. Malcom, and R. J. Chang
Enhanced Granulosa Cell Responsiveness to Follicle-Stimulating Hormone during Insulin Infusion in Women with Polycystic Ovary Syndrome Treated with Pioglitazone
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5624 - 5631.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. S. Legro, R. Azziz, D. Ehrmann, A. G. Fereshetian, M. O'Keefe, and M. N. Ghazzi
Minimal Response of Circulating Lipids in Women with Polycystic Ovary Syndrome to Improvement in Insulin Sensitivity with Troglitazone
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5137 - 5144.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. A. Eagleson, A. B. Bellows, K. Hu, M. B. Gingrich, and J. C. Marshall
Obese Patients with Polycystic Ovary Syndrome: Evidence that Metformin Does Not Restore Sensitivity of the Gonadotropin-Releasing Hormone Pulse Generator to Inhibition by Ovarian Steroids
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5158 - 5162.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Patel, M. S. Coffler, M. H. Dahan, R. Y. Yoo, M. A. Lawson, P. J. Malcom, and R. J. Chang
Increased Luteinizing Hormone Secretion in Women with Polycystic Ovary Syndrome Is Unaltered by Prolonged Insulin Infusion
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5456 - 5461.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
J. M Lord, I. H K Flight, and R. J Norman
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
BMJ, October 25, 2003; 327(7421): 951.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
V. De Leo, A. la Marca, and F. Petraglia
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
Endocr. Rev., October 1, 2003; 24(5): 633 - 667.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Ibanez and F. de Zegher
Flutamide-Metformin Therapy to Reduce Fat Mass in Hyperinsulinemic Ovarian Hyperandrogenism: Effects in Adolescents and in Women on Third-Generation Oral Contraception
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4720 - 4724.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Harborne, R. Fleming, H. Lyall, N. Sattar, and J. Norman
Metformin or Antiandrogen in the Treatment of Hirsutism in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4116 - 4123.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Ibanez, K. Ong, A. Ferrer, R. Amin, D. Dunger, and F. de Zegher
Low-Dose Flutamide-Metformin Therapy Reverses Insulin Resistance and Reduces Fat Mass in Nonobese Adolescents with Ovarian Hyperandrogenism
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2600 - 2606.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
D. Romualdi, M. Guido, M. Ciampelli, M. Giuliani, F. Leoni, C. Perri, and A. Lanzone
Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome
Hum. Reprod., June 1, 2003; 18(6): 1210 - 1218.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Diamanti-Kandarakis, J.-P. Baillargeon, M. J. Iuorno, D. J. Jakubowicz, and J. E. Nestler
A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1927 - 1932.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
V. Jayagopal, E. S. Kilpatrick, P. E. Jennings, D. A. Hepburn, and S. L. Atkin
The Biological Variation of Testosterone and Sex Hormone-Binding Globulin (SHBG) in Polycystic Ovarian Syndrome: Implications for SHBG as a Surrogate Marker of Insulin Resistance
J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1528 - 1533.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
F. Zangeneh, Y. C. Kudva, and A. Basu
Insulin Sensitizers
Mayo Clin. Proc., April 1, 2003; 78(4): 471 - 479.
[Abstract] [PDF]


Home page
Hum ReprodHome page
S. S. George, K. George, C. Irwin, V. Job, R. Selvakumar, V. Jeyaseelan, and M.S. Seshadri
Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial
Hum. Reprod., February 1, 2003; 18(2): 299 - 304.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Morin-Papunen, I. Vauhkonen, R. Koivunen, A. Ruokonen, H. Martikainen, and J. S. Tapanainen
Metformin Versus Ethinyl Estradiol-Cyproterone Acetate in the Treatment of Nonobese Women with Polycystic Ovary Syndrome: A Randomized Study
J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 148 - 156.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
L. Ibanez and F. de Zegher
Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome
Hum. Reprod., January 1, 2003; 18(1): 57 - 60.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
L. A. Stadtmauer, B. C. Wong, and S. Oehninger
Should patients with polycystic ovary syndrome be treated with metformin?: Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction
Hum. Reprod., December 1, 2002; 17(12): 3016 - 3026.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
C. J. Glueck, P. Wang, N. Goldenberg, and L. Sieve-Smith
Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin
Hum. Reprod., November 1, 2002; 17(11): 2858 - 2864.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Schofl, R. Horn, T. Schill, H. W. Schlosser, M. J. Muller, and G. Brabant
Circulating Ghrelin Levels in Patients with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4607 - 4610.
[Abstract] [Full Text] [PDF]


Home page
Diabetes Spectr.Home page
R. Murray
Recognizing the Signs of Metabolic Syndrome and Polycystic Ovary Syndrome in a Caucasian Adolescent Girl: Differentiating Type 2 From Type 1 Diabetes
Diabetes Spectr, October 1, 2002; 15(4): 227 - 231.
[Full Text] [PDF]


Home page
Hum ReprodHome page
E. Seli and A. J. Duleba
Should patients with polycystic ovarian syndrome be treated with metformin?
Hum. Reprod., September 1, 2002; 17(9): 2230 - 2236.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. E. Nestler
Should patients with polycystic ovarian syndrome be treated with metformin?: An enthusiastic endorsement
Hum. Reprod., August 1, 2002; 17(8): 1950 - 1953.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
D. Kirpichnikov, S. I. McFarlane, and J. R. Sowers
Metformin: An Update
Ann Intern Med, July 2, 2002; 137(1): 25 - 33.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
K. Elter, G. Imir, and F. Durmusoglu
Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study
Hum. Reprod., July 1, 2002; 17(7): 1729 - 1737.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Ibanez, C. Valls, A. Ferrer, K. Ong, D. B. Dunger, and F. de Zegher
Additive Effects of Insulin-Sensitizing and Anti-Androgen Treatment in Young, Nonobese Women with Hyperinsulinism, Hyperandrogenism, Dyslipidemia, and Anovulation
J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2870 - 2874.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
Neuropathy, Womens' Health, and Socioeconomic Aspects of Diabetes
Diabetes Care, June 1, 2002; 25(6): 1085 - 1094.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
V. Jayagopal, E. S. Kilpatrick, S. Holding, P. E. Jennings, and S. L. Atkin
The Biological Variation of Insulin Resistance in Polycystic Ovarian Syndrome
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1560 - 1562.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
R. Homburg
Should patients with polycystic ovarian syndrome be treated with metformin?: A note of cautious optimism
Hum. Reprod., April 1, 2002; 17(4): 853 - 856.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. J. Jakubowicz, M. J. Iuorno, S. Jakubowicz, K. A. Roberts, and J. E. Nestler
Effects of Metformin on Early Pregnancy Loss in the Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 524 - 529.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Fleming, Z. E. Hopkinson, A. M. Wallace, I. A. Greer, and N. Sattar
Ovarian Function and Metabolic Factors in Women with Oligomenorrhea Treated with Metformin in a Randomized Double Blind Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 569 - 574.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
H. Yarali, B. O. Yildiz, A. Demirol, H. B. Zeyneloglu, N. Yigit, O. Bukulmez, and Z. Koray
Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial
Hum. Reprod., February 1, 2002; 17(2): 289 - 294.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. H. Y. Ng, N. M. S. Wat, and P. C. Ho
Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial
Hum. Reprod., August 1, 2001; 16(8): 1625 - 1631.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
H. R. Peppard, J. Marfori, M. J. Iuorno, and J. E. Nestler
Prevalence of Polycystic Ovary Syndrome Among Premenopausal Women With Type 2 Diabetes
Diabetes Care, June 1, 2001; 24(6): 1050 - 1052.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Azziz, D. Ehrmann, R. S. Legro, R. W. Whitcomb, R. Hanley, A. G. Fereshetian, M. O’Keefe, and M. N. Ghazzi
Troglitazone Improves Ovulation and Hirsutism in the Polycystic Ovary Syndrome: A Multicenter, Double Blind, Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1626 - 1632.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
D. J. Jakubowicz, M. Seppälä, S. Jakubowicz, O. Rodriguez-Armas, A. Rivas-Santiago, H. Koistinen, R. Koistinen, and J. E. Nestler
Insulin Reduction with Metformin Increases Luteal Phase Serum Glycodelin and Insulin-Like Growth Factor-Binding Protein 1 Concentrations and Enhances Uterine Vascularity and Blood Flow in the Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1126 - 1133.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
J. E. Nestler
Metformin and the Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1430 - 1430.
[Full Text]


Home page
DTBHome page
Tackling polycystic ovary syndrome
DTB, January 1, 2001; 39(1): 1 - 5.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. E. Oberfield
Metabolic Lessons from the Study of Young Adolescents with Polycystic Ovary Syndrome--Is Insulin, Indeed, the Culprit?
J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3520 - 3525.
[Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Ibáñez, C. Valls, N. Potau, M. V. Marcos, and F. de Zegher
Sensitization to Insulin in Adolescent Girls to Normalize Hirsutism, Hyperandrogenism, Oligomenorrhea, Dyslipidemia, and Hyperinsulinism after Precocious Pubarche
J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3526 - 3530.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
L. C. Morin-Papunen, I. Vauhkonen, R. M. Koivunen, A. Ruokonen, H. K. Martikainen, and J. S. Tapanainen
Endocrine and Metabolic Effects of Metformin Versus Ethinyl Estradiol-Cyproterone Acetate in Obese Women with Polycystic Ovary Syndrome: A Randomized Study
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3161 - 3168.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Pasquali, A. Gambineri, D. Biscotti, V. Vicennati, L. Gagliardi, D. Colitta, S. Fiorini, G. E. Cognigni, M. Filicori, and A. M. Morselli-Labate
Effect of Long-Term Treatment with Metformin Added to Hypocaloric Diet on Body Composition, Fat Distribution, and Androgen and Insulin Levels in Abdominally Obese Women with and without the Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2767 - 2774.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society